Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Share-based Compensation (2016 - 2025)

Gyre Therapeutics (GYRE) has disclosed Share-based Compensation for 16 consecutive years, with $4.6 million as the latest value for Q4 2025.

  • Quarterly Share-based Compensation rose 710.76% to $4.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $7.2 million through Dec 2025, up 761.25% year-over-year, with the annual reading at $7.2 million for FY2025, 761.25% up from the prior year.
  • Share-based Compensation for Q4 2025 was $4.6 million at Gyre Therapeutics, up from $1.1 million in the prior quarter.
  • The five-year high for Share-based Compensation was $12.3 million in Q4 2022, with the low at $11000.0 in Q1 2024.
  • Average Share-based Compensation over 5 years is $1.6 million, with a median of $541000.0 recorded in 2022.
  • The sharpest move saw Share-based Compensation crashed 94.76% in 2024, then skyrocketed 5562.5% in 2025.
  • Over 5 years, Share-based Compensation stood at $683000.0 in 2021, then surged by 1698.1% to $12.3 million in 2022, then plummeted by 43.95% to $6.9 million in 2023, then tumbled by 91.76% to $567000.0 in 2024, then surged by 710.76% to $4.6 million in 2025.
  • According to Business Quant data, Share-based Compensation over the past three periods came in at $4.6 million, $1.1 million, and $906000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.